Tempus AI (NASDAQ:TEM) Stock Price Target Raised at JPMorgan Chase & Co.

Tempus AI (NASDAQ:TEM) had its price target increased by investment analysts at JPMorgan Chase & Co. from $45.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 2.46% from the stock’s current price.

TEM has been the topic of a number of other reports. Roth Capital initiated coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price on the stock. UBS Group assumed coverage on Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and upped their target price for the company from $56.00 to $76.00 in a report on Tuesday, September 1st. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Finally, BTIG Research lifted their price target on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Eleven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $72.37.

Tempus AI Price Performance

NASDAQ:TEM traded up $0.10 during trading hours on Wednesday, reaching $68.32. 6,007,028 shares of the company’s stock were exchanged, compared to its average volume of 6,222,563. The company has a market capitalization of $12.33 billion, a P/E ratio of -47.44 and a beta of 3.54. Tempus AI has a 12 month low of $40.77 and a 12 month high of $97.25. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The business’s 50-day simple moving average is $66.88 and its two-hundred day simple moving average is $56.07.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.22) earnings per share. Sell-side analysts expect that Tempus AI will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Ryan Bartolucci sold 7,062 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the transaction, the chief accounting officer owned 60,804 shares of the company’s stock, valued at approximately $4,560,300. This trade represents a 10.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of Tempus AI stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $49,000.00. Following the transaction, the chief executive officer owned 15,874 shares in the company, valued at approximately $1,111,180. The trade was a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,280,965 shares of company stock worth $80,397,564 in the last quarter. Corporate insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. boosted its position in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares during the period. Eagle Health Investments LP acquired a new position in Tempus AI during the first quarter valued at approximately $11,588,000. Swiss National Bank raised its position in shares of Tempus AI by 0.3% in the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after purchasing an additional 600 shares during the period. Finally, Aristotle Atlantic Partners LLC acquired a new position in Tempus AI in the 1st quarter valued at $6,179,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.